Source: Auxly.
  • Auxly (XLY) announced a $3.36 million private placement with institutional investors
  • Net proceeds will be used for working capital and general corporate purposes
  • The offering is expected to close during the week of February 13, 2023
  • Auxly is a leading Canadian cannabis consumer packaged goods company headquartered in Toronto
  • Auxly Cannabis Group (XLY) opened with a loss of 12.50 per cent, trading at $0.035 per share

Auxly (XLY) announced a $3.36 million private placement with institutional investors.

The investors have agreed to purchase 96,000,000 common shares and 96,000,000 share purchase warrants.

Each warrant enables the purchase of one XLY common share for $0.045 up to 60 months from the date of issuance.

Net proceeds will be used for working capital and general corporate purposes.

The offering is expected to close during the week of February 13, 2023.

All shares and warrants under the private placement will be offered exclusively to U.S. investors on the same basis pursuant to exemptions from registration requirements under the United States Securities Act of 1933.

Additionally, Auxly seeks to amend the terms of 27,381,500 share purchase warrants from a bought-deal offering completed on June 14, 2021. Changes include reducing the warrants’ exercise price from $0.38 to $0.045 per share and extending their expiry date from June 14, 2024 to June 14, 2026. The amendments are expected to take effect by late February or early March.

Auxly is a leading Canadian cannabis consumer packaged goods company headquartered in Toronto.

Auxly Cannabis Group (XLY) opened with a loss of 12.50 per cent, trading at $0.035 per share.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.